POS0030 SARCOIDOSIS INCIDENCE IN A NORTHERN SPANISH HEALTH REGION.
Authors: C. Álvarez-Reguera, R. Fernández-Ramón, J. J. Gaitán-Valdizán, J. L. Martín-Varillas, L. Sanchez-Bilbao, D. Martínez-López, I. González-Mazón, R. Demetrio-Pablo, M. Á. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2021)

Background: Sarcoidosis is a systemic and potentially severe disease (1). Its incidence varies widely worldwide. Objectives: The aim of this study was to estimate the sarcoidosis incidence in a Northern Spanish population-based cohort. Methods: All incident cases of sarcoidosis between January 1999 and December 2019 in a tertiary hospital were reviewed. Inclusion criteria were a ) diagnosis of sarcoidosis according to ATS/ERS/WASOG (Eur Respir J. 1999; 14:735-7 ) and b ) patients residing in our health region. Incidence between 1999 and 2019 was estimated by sex, age, and year of diagnosis. Results: From a total of 384 patients diagnosed with sarcoidosis, 234 (129 women/ 105 men) met the inclusion criteria and were finally included in the study. Mean age of the cohort at diagnosis was 48.43±14.83 years (46.95±14.50 in males; 49.63±15.04 in females, p=0.12). Annual incidence during 1999-2019 period was 3.56 per 100,000 population (3.32 per 100,000 in males and 3.72 per 100,000 in females). An upward trend in annual incidence over time was observed with rates ranging from 1.73 per 100,000 inhabitants in 1999 to 6.91 per 100,000 inhabitants in 2016 (Figure 1). Overall, sarcoidosis was predominantly diagnosed during middle adulthood. A bimodal distribution of age-specific incidence rates was observed in both sexes with two peaks in the age groups of 30-39 (4.98 per 100,000) and 60-69 years (5.12 per 100,000) in men, and in 40-49 (6.45 per 100,000) and 60-69 years (5.94 per 100,000) in women. Comparative studies with other regions are summarize in Table 1. Conclusion: A progressive increase in incident sarcoidosis is observed. The estimated incidence of sarcoidosis in this study (3.56 per 100,000) was like that of other Mediterranean countries (2). No gender predominance was observed. Demographics variations, changes in practice patters or diagnostic test improvements could explain the upward trend in sarcoidosis incidence detected in our study. Consistent with previous studies, male presented an incidence peak 10 years earlier than female (3-5 ). References: [1]Riancho-Zarrabeitia L, et al. Clin Exp Rheumatol 2014; 32(2): 275-84. PMID: 24321604 [2]Brito-Zerón P, et al. Clin Exp Rheumatol. 2019;37(6):1052–64. [3]Arkema E V., et al. Eur Respir J. 2016;48(6):1690-9. [4]Yoon H, et al. Am J Respir Crit Care Med. 2018;197(MeetingAbstracts):1-8. [5]Ungprasert P, et. Mayo Clin Proc. 2016 Feb;91(2):183-8. Figure 1. Annual incidence of sarcoidosis in 1999-2019 (A) Table 1. Sarcoidosis incidence rates reported in the literature. Study, year Country, data source Time period Incident cases Incidence per 100,000 persons-year Pietinalho, 1995 Finland, hospital database 1984 1,378 11.4 Pietinalho, 1995 Japan, Hokkaido, hospital database 1984 288 1.0 Yigla, 2002 Israel, hospital database 1980-1996 120 0.8 Byg, 2003 Denmark, Danish National Patient Registry 1980-1994 5,536 7.2 Gribbin, 2006 UK, Health Improvement Network 1990-2003 1,019 5.0 Gillman, 2007 Australia, Victoria, hospital database 1995-2005 122 4.4-6.3 Haraldsdottir, 2007 Iceland, hospital database 1981-2003 235 3.8 Musellin, 2009 Turkey, healthcare providers 2004-2006 293 4.0 Deubelbeiss, 2010 Switzerland, Swiss Federal Office for Statistics 2002-2005 2,925 7.0 Kowalska, 2014 Poland, Katowice, National Health Fund 2006-2010 1,217 3.8-4.5 Arkema, 2016 Sweden, National Patient Register 2003-2013 10,787 10.4-14.8 Baughman, 2016 USA, Optum Health Care Database 2010-2013 29,372 African American: 17.8; Caucasian: 8.1; Hispanic: 4.3; Asian: 3.2 Duchemann, 2017 France, Seine-Saint-Denise County 2012 361 4.9 Škopljanac, 2017 Croatia, Split- Dalmatia County, hospital database 1986-2015 318 3.1-3.4 Yoon, 2018 Korea, National Health Insurance 2007-2016 4,791 0.85 Fidler, 2019 Canada, Ontario, health administrative data 1996-2015 18,550 6.8-7.9 Fernandez, 2011 Spain, Leon, hospital database 2001-2008 118 4.51 Present study, 2020 Spain, Santander, hospital database 1999-2019 234 3.56 Disclosure of Interests: Carmen Álvarez-Reguera: None declared, Raúl Fernández-Ramón: None declared, Jorge Javier Gaitán-Valdizán: None declared, José Luis Martín-Varillas: None declared, Lara Sanchez-Bilbao: None declared, David Martínez-López: None declared, Iñigo González-Mazón: None declared, Rosalía Demetrio-Pablo: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche.